SHP2 Inhibitor BBP-398 in Combination With Sotorasib in Patients With Advanced Solid Tumors and a KRAS-G12C Mutation

NCT05480865 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

28

Enrollment

INDUSTRY

Sponsor class

Stopped Business Reasons

Conditions

Solid Tumor, Adult
Metastatic Solid Tumor
Metastatic NSCLC
Non Small Cell Lung Cancer

Interventions

DRUG: BBP-398
DRUG: sotorasib

Sponsor

Navire Pharma Inc., a BridgeBio company

Collaborators

[object Object]